A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
Stopped Study treatment is to use TS-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer, which may be less clinical benefit compared to combination therapy according to current trend at investigators' discretion.
Conditions
- Resected Pancreatic Cancer
- Pancreatic Cancer
- Adjuvant Chemotherapy
Interventions
Sponsor
TTY Biopharm
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]